Hong-yu Li Institution Verified

OverviewAI-generated summary

Hong-yu Li's research focuses on the development of novel therapeutic agents, with a particular emphasis on cancer treatment. Li is the Principal Investigator on an NIH/National Cancer Institute grant for the "Drug Development of Skp2 PROTACs in Cancer." This project, funded at $1, aims to advance the development of proteolysis-targeting chimeras (PROTACs) targeting Skp2, a protein implicated in various cancers.

Li's recent publication, "An unprecedented potent inhibitor of MV4-11 cells: investigations into the mechanism of action beyond FLT3 inhibition" (2026), explores the cellular mechanisms of a newly identified compound's anti-cancer effects. This work investigates how the inhibitor impacts MV4-11 cells, a leukemia cell line, and examines its activity beyond the known FLT3 inhibition pathway. Li maintains an active laboratory website to disseminate research findings.

Metrics

• Publications: 1